Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Work Productivity in Hyperventilation Syndrome (WHY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03292523
Recruitment Status : Recruiting
First Posted : September 25, 2017
Last Update Posted : March 11, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
Hyperventilation syndrome is associated with impaired quality of life. The aim of the study is to assess the relationship between work productivity, including absenteeism and presenteeism, and the severity of hyperventilation syndrome

Condition or disease Intervention/treatment
Hyperventilation Syndrome Other: questionnaire

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Work Productivity in Hyperventilation Syndrome
Actual Study Start Date : February 6, 2018
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

Group/Cohort Intervention/treatment
Hyperventilation syndrome Other: questionnaire
Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).




Primary Outcome Measures :
  1. Association between the WPAI score and the Nijmegen score [ Time Frame: At the time of diagnosis (Baseline) ]

Secondary Outcome Measures :
  1. Association between the WPAI score and dyspnea scales [ Time Frame: At the time of diagnosis (Baseline) ]
  2. Association between the WPAI score and quality of life scores [ Time Frame: At the time of diagnosis (Baseline) ]
  3. Association between the WPAI score and PaCO2 [ Time Frame: At the time of diagnosis (Baseline) ]
  4. Association between the WPAI score and the Cognitive Failure Questionnaire score [ Time Frame: At the time of diagnosis (Baseline) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with confirmed hyperventilation syndrome, virgin of any treatment.
Criteria

Inclusion Criteria:

  • Holders of employment contracts for at least 8 days
  • Diagnosis of hyperventilation syndrome confirmed by:

Compatible symptoms and at least two symptoms reproduced by the hyperventilation challenge test: Nijmegen's score> 23 ; Demonstration of alveolar hyperventilation ( Either on rest blood and / or at rest (PaCO2 at rest <36 mmHg and D (A-a) O2 normal; Either during the HV test (increased recovery time of the basic PETCO2 after voluntary hyperventilation (greater than 5 minutes)

Exclusion Criteria:

  • Existence of another chronic pulmonary disease (asthma, bronchial dilation, COPD, diffuse interstitial pneumonia, neuromuscular pathology ...) or cardiac (rhythm disorder, ischemic heart disease ...) which can participate in dyspnea
  • Psychiatric illness / psychotropic treatment
  • Pregnancy
  • Patient already included in a clinical research protocol involving new therapeutics may not be included in this protocol
  • Specific physiotherapy or previous training

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03292523


Contacts
Layout table for location contacts
Contact: Cécile Chenivesse, MD 3.20.44.59.48 ext +33 cecile.chenivesse@chru-lille.fr

Locations
Layout table for location information
France
Hôpital Calmette,CHU Recruiting
Lille, France
Principal Investigator: Cecile Chenivesse         
Sponsors and Collaborators
University Hospital, Lille
Investigators
Layout table for investigator information
Principal Investigator: Cécile Chenivesse, MD University Hospital, Lille
Layout table for additonal information
Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT03292523    
Other Study ID Numbers: 2016_68
2017-A01542-51 ( Other Identifier: ID-RCB number, ANSM )
First Posted: September 25, 2017    Key Record Dates
Last Update Posted: March 11, 2021
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Lille:
Hyperventilation syndrome
Work productivity
Absenteeism
Presenteeism
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperventilation
Syndrome
Disease
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory